Tags

Type your tag names separated by a space and hit enter

Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
PLoS One. 2015; 10(11):e0142754.Plos

Abstract

BACKGROUND

The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization.

METHODS

A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry.

RESULTS

Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among <4 year-olds (928) and ≥65 years (1,721). VE against hospitalization with laboratory-confirmed A(H1N1)pdm09 was 70% (39-85%) overall and (91%; 62-98%) ≥ 14 days following vaccination.

DISCUSSION

Our data suggest that the adjuvanted A(H1N1)pdm09 vaccine was effective in preventing about 55-60% of P&I hospitalizations among children and younger adults who were at much higher risk of infection. Unfortunately, the vaccine was less effective among 65 or older adults. Despite that the vaccine still had a significant population-based impact especially among the very young (<5) and the older (≥ 65 years).

Authors+Show Affiliations

Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada. Manitoba Health, Winnipeg, Manitoba, Canada.Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Manitoba Health, Winnipeg, Manitoba, Canada.Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada. Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada. Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada. Manitoba Health, Winnipeg, Manitoba, Canada.Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada. Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada. Manitoba Health, Winnipeg, Manitoba, Canada.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26600435

Citation

Mahmud, Salaheddin M., et al. "Did the H1N1 Vaccine Reduce the Risk of Admission With Influenza and Pneumonia During the Pandemic?" PloS One, vol. 10, no. 11, 2015, pp. e0142754.
Mahmud SM, Bozat-Emre S, Hammond G, et al. Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic? PLoS One. 2015;10(11):e0142754.
Mahmud, S. M., Bozat-Emre, S., Hammond, G., Elliott, L., & Van Caeseele, P. (2015). Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic? PloS One, 10(11), e0142754. https://doi.org/10.1371/journal.pone.0142754
Mahmud SM, et al. Did the H1N1 Vaccine Reduce the Risk of Admission With Influenza and Pneumonia During the Pandemic. PLoS One. 2015;10(11):e0142754. PubMed PMID: 26600435.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic? AU - Mahmud,Salaheddin M, AU - Bozat-Emre,Songul, AU - Hammond,Gregory, AU - Elliott,Lawrence, AU - Van Caeseele,Paul, Y1 - 2015/11/23/ PY - 2015/09/04/received PY - 2015/10/26/accepted PY - 2015/11/25/entrez PY - 2015/11/26/pubmed PY - 2016/6/24/medline SP - e0142754 EP - e0142754 JF - PloS one JO - PLoS One VL - 10 IS - 11 N2 - BACKGROUND: The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization. METHODS: A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry. RESULTS: Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among <4 year-olds (928) and ≥65 years (1,721). VE against hospitalization with laboratory-confirmed A(H1N1)pdm09 was 70% (39-85%) overall and (91%; 62-98%) ≥ 14 days following vaccination. DISCUSSION: Our data suggest that the adjuvanted A(H1N1)pdm09 vaccine was effective in preventing about 55-60% of P&I hospitalizations among children and younger adults who were at much higher risk of infection. Unfortunately, the vaccine was less effective among 65 or older adults. Despite that the vaccine still had a significant population-based impact especially among the very young (<5) and the older (≥ 65 years). SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/26600435/Did_the_H1N1_Vaccine_Reduce_the_Risk_of_Admission_with_Influenza_and_Pneumonia_during_the_Pandemic L2 - https://dx.plos.org/10.1371/journal.pone.0142754 DB - PRIME DP - Unbound Medicine ER -